El En SpA
F:EE5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
El En SpA
F:EE5
|
IT |
El En SpA
El.En. SpA makes laser systems used in medical and industrial settings. On the medical side, it sells lasers for dermatology, aesthetics, surgery, and other specialist treatments. On the industrial side, it supplies laser machines for cutting, marking, welding, and other manufacturing work. Its customers are hospitals, clinics, doctors, beauty and aesthetic centers, and industrial companies that need precision laser equipment. The company also supports these products with accessories, software, service, and spare parts, which helps keep customers tied to its equipment over time. El.En. makes money mainly by selling laser machines and related consumables and services through a mix of direct sales and distributors. Its business is different because it sits in a niche where physics, optics, and application know-how matter a lot, so customers buy not just a machine but a specialized tool built for a specific medical or manufacturing job.
El.En. SpA makes laser systems used in medical and industrial settings. On the medical side, it sells lasers for dermatology, aesthetics, surgery, and other specialist treatments. On the industrial side, it supplies laser machines for cutting, marking, welding, and other manufacturing work.
Its customers are hospitals, clinics, doctors, beauty and aesthetic centers, and industrial companies that need precision laser equipment. The company also supports these products with accessories, software, service, and spare parts, which helps keep customers tied to its equipment over time.
El.En. makes money mainly by selling laser machines and related consumables and services through a mix of direct sales and distributors. Its business is different because it sits in a niche where physics, optics, and application know-how matter a lot, so customers buy not just a machine but a specialized tool built for a specific medical or manufacturing job.
Profitability: Q3 was especially strong in terms of profitability, with a 3.8% increase in EBIT versus last year, driven by the medical division.
Medical Division: Medical revenue grew 4.6% in the first 9 months, or over 10% excluding the Cynosure contract and Japanese subsidiary effects, and gross margins improved significantly.
Industrial Division: Industrial revenue rose just 1.9%, with the cutting business underperforming due to delayed revenues and competitive pressures.
Cash Position: The group generated strong cash flow, with the net financial position increasing by EUR 47 million in Q3, aided by the sale of a majority stake in a Chinese subsidiary.
Guidance: Management expects to beat 2024 in both revenue and EBIT, targeting EUR 23 million in EBIT for Q4 2025.
Geographic Performance: The Italian market was a standout, with medical revenues up 27%; European markets also performed well, while U.S. industrial sales suffered from M&A-related uncertainty.
M&A Strategy: The company is exploring small, potentially accretive acquisitions mainly in medical but also industrial; transformational deals are only at early evaluation stages.
